Thrivent Financial for Lutherans grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 8.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 125,262 shares of the company’s stock after purchasing an additional 9,318 shares during the period. Thrivent Financial for Lutherans’ holdings in Medpace were worth $70,353,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Pinnacle Associates Ltd. acquired a new stake in shares of Medpace in the 4th quarter valued at $593,000. Mainsail Asset Management LLC acquired a new stake in shares of Medpace in the 4th quarter valued at $229,000. Oregon Public Employees Retirement Fund increased its stake in shares of Medpace by 0.9% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,460 shares of the company’s stock valued at $2,505,000 after buying an additional 40 shares during the period. Independent Advisor Alliance increased its stake in shares of Medpace by 37.4% in the 4th quarter. Independent Advisor Alliance now owns 1,434 shares of the company’s stock valued at $805,000 after buying an additional 390 shares during the period. Finally, Legacy Financial Advisors Inc. acquired a new stake in shares of Medpace in the 4th quarter valued at $290,000. 77.98% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Medpace
In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.
Medpace Stock Down 0.9%
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the firm earned $3.67 earnings per share. The firm’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently commented on MEDP shares. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Royal Bank Of Canada decreased their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Barclays decreased their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Finally, Robert W. Baird decreased their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Medpace has an average rating of “Hold” and an average price target of $467.08.
View Our Latest Stock Report on MEDP
Key Stories Impacting Medpace
Here are the key news stories impacting Medpace this week:
- Negative Sentiment: Multiple law firms issued fresh reminders about an already filed class action alleging Medpace misled investors during the April 22, 2025 to February 9, 2026 period, with lead-plaintiff deadlines approaching in early June. Article Title
- Negative Sentiment: New and repeated class-action notices are keeping Medpace’s alleged investor-harm claims in the spotlight, which can weigh on sentiment and increase legal overhang for the stock. Article Title
- Negative Sentiment: Coverage specifically highlighting Medpace’s backlog disclosures and governance suggests investors are scrutinizing the quality of the company’s operational reporting, adding to uncertainty around future performance. Article Title
- Negative Sentiment: Additional law firm notices from Faruqi & Faruqi, The Gross Law Firm, BFA Law, Rosen, Pomerantz, DJS Law Group, and Schall keep the class action front and center, reinforcing a negative near-term narrative for MEDP. Article Title
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
- Five stocks we like better than Medpace
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
